The Senhance System Used to Perform Inguinal and Ventral Hernia
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
TransEnterix, Inc. (NYSE MKT: TRXC) ("TransEnterix"), a medical device
company that is pioneering the use of robotics to improve minimally
invasive surgery, today announced that it has expanded the clinical
adoption of the Senhance Robotic Surgical System ("the Senhance") to
include a full range of hernia repair surgeries.
Hernia repairs represent one of the largest procedural opportunities for
the Senhance. Millennium Research Group has estimated that during 2017,
there will be a total of 1,080,400 hernia repair surgeries in Europe1
and 1,156,300 hernia repair surgeries in the United States2.
"Robotic hernia repair with the Senhance system represents a significant
procedural area for our technology," said Todd M. Pope, President and
CEO of TransEnterix. "Hernia repairs, both inguinal and ventral, are
amongst the most common surgical procedures performed worldwide. These
procedures also represent one of the fastest growing uses of robotics in
surgery. The introduction of Senhance to provide robotic assistance in
these procedures brings a system with haptic feedback and attractive
procedural costs to these operations for the first time."
St. Marien-Krankenhaus Siegen in Germany, a major hernia repair center
in Germany that performs over 500 hernia repairs annually, was the first
site to begin using the Senhance for unilateral and bilateral inguinal
hernia repairs as well as ventral hernia repairs. Dr. Dietmar Stephan
and Prof. Dr. Frank Willeke performed up to three robotic hernia
surgeries per day with the Senhance during the first weeks of its
clinical use at the hospital. This allows the team to adopt Senhance to
include the day's full operating schedule.
"We are pleased to offer robotic hernia repair utilizing the Senhance
Robotic System, and all our operations utilizing this advanced
technology have been performed with precision, safety and efficiency.
The 3D visualization and precise control of the robotic instruments and
camera are very helpful during delicate surgical tasks. The haptic
feedback of the system is vital, and it allows me to feel the location
of critical structures such as the pubic bone which aren't always
visible," said Dr. Dietmar Stephan, Director of the Center for Minimally
Invasive Surgery at St. Marien. "The Senhance is a significant
progression in the field of minimally invasive hernia repair, and allows
me to fully incorporate robotics into my hernia practice without having
to justify high additional procedural costs."
TransEnterix will be exhibiting the Senhance Surgical System at two
major surgical conferences: The Society of American Gastrointestinal and
Endoscopic Surgeons in Houston, Texas which will be held March 22-25,
2017, and the Kongress Deutsche Gesellschaft für Chirurgen, the largest
general surgery meeting in Germany, in Munich being held March 21-23,
2017. The Senhance will be available for surgeon evaluations at both
events, and Dr. Dietmar Stephan will be discussing his technique of
robotic hernia repair with Senhance at the German surgical meeting.
TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options. The company is focused on the commercialization of
the Senhance Surgical Robotic System, a multi-port robotic system that
brings the advantages of robotic surgery to patients while enabling
surgeons with innovative technology such as haptic feedback and eye
sensing camera control. The company also developed the SurgiBot™ System,
a single-port, robotically enhanced laparoscopic surgical platform. The
Senhance Surgical Robotic System has been granted a CE Mark but is not
currently available for sale in the United States. For more information,
visit the TransEnterix website at www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™
Surgical Robotic System and our current regulatory and commercialization
plans for this product. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are subject to
risks and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the introduction of the Senhance System
to provide robotic assistance in hernia procedures brings a system with
haptic feedback and attractive procedural costs to these operations for
the first time. For a discussion of the risks and uncertainties
associated with TransEnterix's business, please review our filings with
the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K filed on March 6, 2017 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as of
the date of this press release and speak only as of the
origination date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.
1 Millennium Research Group, Laparoscopic Devices
Europe 2014 Market Analysis
2 Millennium Research Group, Medtech 360:
Laparoscopic Devices US 2016 Market Analysis
View source version on businesswire.com: http://www.businesswire.com/news/home/20170322005343/en/
For TransEnterix, Inc.
For EU: Conrad Harrington, +44 (0)20 3178 8914
US: Hannah Dunning, +1-415-618-8750
Source: TransEnterix, Inc.
News Provided by Acquire Media